您所在的位置: 首页 --> 导师团队 --> 陆哲明

导师基本信息

  • 姓名:陆哲明
  • 性别:
  • 民族:汉族
  • 科室:生化与分子生物学研究室
  • 职称:研究员 ,副教授
  • 专业:肿瘤学
  • E-MAIL: zheminglu@163.com

学术论文 | 研究方向 | 专利 | 科研项目 | 招生计划

Chaoting Zhang#, Qin Tan#, Shance Li#, Luyan Shen, Jingtao Zhang, Ying Liu, Wenjun Yang*, Zheming Lu*,Journal for Immunotherapy of Cancer,2021,9(7):e002516

Liang Yun#, Liu Hui#, Lu Zheming#, Lei Wen, Zhang Chaoting, Li Ping, Liang Aibin*, Young Ken H*, Qian Wenbin* CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies,J Hematol Oncol.,2021;14(1):26

Hui Liu#, Wen Lei #, Chaoting Zhang#, Chunmei Yang , Juying Wei , Qunyi Guo , Xiaojun Guo , Zhilu Chen , Ying Lu, Ken H Young*, Zheming Lu* , Wenbin Qian*. CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma,Clinical Cancer Research,2021,27(2):473-484.

Chaoting Zhang#, Heyilimu Palashati#, Zhuona Rong, Ningjing Lin, Luyan Shen, Ying Liu, Shance Li, Bentong Yu*, Wenjun Yang*, Zheming Lu* Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies,Molecular Cancer,2020,19(1):162

Tan Qin, Zhang Chaoting*, Yang Wenjun, Liu Ying, Heyilimu Palashati, Feng Dongdong, Xing Liying, Ke Yang*, Lu Zheming* Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma.,Journal for immunotherapy of cancer,2019,7(1):232

Ningjing Lin #, Wenjing Ku#, Yuqin Song, Jun Zhu*, Zheming Lu* Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type,Oncologist,2019,24(9):e905-e913

Zhang C#, Ding H#, Huang H, Palashati H, Miao Y, Xiong H*, Lu Z*. TCR repertoire intratumor heterogeneity of CD4+ and CD8+ T cells in centers and margins of localized lung adenocarcinomas.,Int J Cancer.,2019;144(4):818-827.

Cui C, Tian X, Wu J, Zhang C, Tan Q, Guan X, Dong B, Zhao M, Lu Z, Hao C. T cell receptor β-chain repertoire analysis of tumor-infiltrating lymphocytes in pancreatic cancer.,Cancer Sci. ,2019 Jan;110(1):61-71.

Zhang C#, Huang H, Miao Y, Xiong H*, Lu Z*. Clonal distribution and intratumour heterogeneity of the B-cell repertoire in oesophageal squamous cell carcinoma..,J Pathol,2018 Nov;246(3):323-330

Tan Qin, Ku Wenjing, Zhang Chaoting, Heyilimu Palashati, Tian Yuan, Ke Yang* & Lu Zheming*. Mutation analysis of the EBV-lymphoblastoid cell line cautions their use as antigen-presenting cells.,Immunology & Cell Biology,2018,96: 204–211

Zhang C#, Palashati H#, Tan Q, Ku W, Miao Y, Xiong H*, Lu Z*. Immediate and substantial evolution of T-cell repertoire in peripheral blood and tumor microenvironment of patients with esophageal squamous cell carcinoma treated with preoperative chemotherapy., Carcinogenesis. ,2018 Dec 13;39(11):1389-1398.

Lu Zheming*#; Zhang Chaoting; Sheng Jindong, Shen Jing; Liu Baoguo. T cell receptor β-chain repertoire analysis reveals the association between neoantigens and tumour-infiltrating lymphocytes in multifocal papillary thyroid carcinoma.,International Journal Cancer,2017;141(2):377-382

Lu Zheming#;Zhang Yujie;Feng Dongdong, Sheng Jindong;Yang Wenjun;Liu Baoguo. Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma..,oncotarget ,doi: 10.18632/.17412.

Liu Y, Pan Y, Gao W, Ke Y, Lu Z*. Whole-Genome Analysis of Human Papillomavirus Types 16, 18, and 58 Isolated from Cervical Precancer and Cancer Samples in Chinese Women.,Sci Rep. ,7(1):263.

一种同时表达靶向CD19和CD20的CAR与PD1-CD28嵌合受体的慢病毒载体, 发明专利, 第1完成人 , 国家知识产权局, 中国, 2020.7

高效获得抗肿瘤TCR及其功能研究, 课题负责人 , 2020.1.1~2023.12.31, 国家自然科学基金

抗肿瘤TCR的克隆及在食管鳞癌过继细胞治疗中的临床前研究, 课题负责人 , 2017.1.1~2020.12.31, 北京市自然科学基金/7171001

免疫图谱动态检测预测肝癌Nivolumab治疗效果, 课题负责人 , 2017.2.1~2020.8.31, 北京市科委“首都临床特色应用研究”专项/Z171100001017136

研究生招生计划
招生年度 招生专业 学位级别 学位类型 研究方向 选拔方式
2022 肿瘤学 硕士 科学学位 肿瘤免疫学,肿瘤个体化免疫治疗 全国统考

社会任职

  • 中华抗癌学会病因学分会常务委员
  • 中国医药质量管理协会细胞治疗质量控制与研究专业委员会委员

学习、工作经历

  • 2018.8.1~2020.8.11,北京市肿瘤防治研究所 生化与分子生物学研究室 研究员
  • 2010.10.4~2018.7.31,北京市肿瘤防治研究所 副研究员
  • 2008.5.6~2010.9.6,北京市肿瘤防治研究所 助理研究员
  • 2006.7.14~2008.4.14,Duke University, Medical Center博士后
  • 2004.9.14~2006.6.14,Harvard University, Harvard Medical School博士后